JP4982610B2 - 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー - Google Patents

疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー Download PDF

Info

Publication number
JP4982610B2
JP4982610B2 JP2010530497A JP2010530497A JP4982610B2 JP 4982610 B2 JP4982610 B2 JP 4982610B2 JP 2010530497 A JP2010530497 A JP 2010530497A JP 2010530497 A JP2010530497 A JP 2010530497A JP 4982610 B2 JP4982610 B2 JP 4982610B2
Authority
JP
Japan
Prior art keywords
disease
activity
disease progression
inflammatory
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010530497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011501176A (ja
JP2011501176A5 (enExample
Inventor
ヤルカネン、シルパ
サルミ、マルコ
ヤルカネン、マルック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of JP2011501176A publication Critical patent/JP2011501176A/ja
Publication of JP2011501176A5 publication Critical patent/JP2011501176A5/ja
Application granted granted Critical
Publication of JP4982610B2 publication Critical patent/JP4982610B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2010530497A 2007-10-24 2008-10-15 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー Expired - Fee Related JP4982610B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795 2007-10-24
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012098081A Division JP5619810B2 (ja) 2007-10-24 2012-04-23 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー

Publications (3)

Publication Number Publication Date
JP2011501176A JP2011501176A (ja) 2011-01-06
JP2011501176A5 JP2011501176A5 (enExample) 2012-04-19
JP4982610B2 true JP4982610B2 (ja) 2012-07-25

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010530497A Expired - Fee Related JP4982610B2 (ja) 2007-10-24 2008-10-15 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー
JP2012098081A Expired - Fee Related JP5619810B2 (ja) 2007-10-24 2012-04-23 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012098081A Expired - Fee Related JP5619810B2 (ja) 2007-10-24 2012-04-23 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー

Country Status (14)

Country Link
US (1) US20100209942A1 (enExample)
EP (2) EP2201376B1 (enExample)
JP (2) JP4982610B2 (enExample)
KR (2) KR20100059902A (enExample)
CA (1) CA2702635A1 (enExample)
CY (2) CY1113403T1 (enExample)
DK (2) DK2503338T3 (enExample)
ES (2) ES2389751T3 (enExample)
FI (1) FI20070795A0 (enExample)
HR (2) HRP20120743T1 (enExample)
PL (2) PL2503338T3 (enExample)
PT (2) PT2201376E (enExample)
SI (2) SI2503338T1 (enExample)
WO (1) WO2009053523A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
SG10201505724SA (en) 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
DK2956772T3 (en) * 2013-02-14 2018-08-13 Faron Pharmaceuticals Oy A PROCEDURE FOR DETERMINING ACUTE LUNG FAILURE (ARDS) RELATED BIOMARKERS, A PROCEDURE FOR MONITORING DEVELOPMENT AND TREATMENT OF ARDS BY A PATIENT
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients
GB201715115D0 (en) 2017-09-19 2017-11-01 Univ London Queen Mary Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0854934A4 (en) * 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
AU7310496A (en) * 1995-10-13 1997-04-30 Imperial College Of Science, Technology And Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP1608400B1 (en) * 2003-03-28 2010-06-23 Faron Pharmaceuticals OY Elevation of adenosine level by cytokine-induced expression of cd73
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
CN1835962A (zh) * 2003-06-03 2006-09-20 加利福尼亚大学董事会 利用乙酰化二糖治疗疾病的组合物与方法
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
CA2657576C (en) * 2006-07-14 2023-10-31 The Regents Of The University Of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
JP2011501176A (ja) 2011-01-06
EP2503338B1 (en) 2014-12-24
ES2389751T3 (es) 2012-10-31
PL2503338T3 (pl) 2015-06-30
CY1116089T1 (el) 2017-02-08
SI2503338T1 (sl) 2015-06-30
EP2201376A4 (en) 2011-03-23
KR20160029869A (ko) 2016-03-15
EP2503338A2 (en) 2012-09-26
JP2012159514A (ja) 2012-08-23
HRP20150181T1 (hr) 2015-06-19
WO2009053523A1 (en) 2009-04-30
KR20100059902A (ko) 2010-06-04
US20100209942A1 (en) 2010-08-19
ES2532361T3 (es) 2015-03-26
EP2201376B1 (en) 2012-08-08
PT2201376E (pt) 2012-08-20
CY1113403T1 (el) 2016-06-22
PL2201376T3 (pl) 2013-01-31
FI20070795A0 (fi) 2007-10-24
DK2503338T3 (en) 2015-03-09
PT2503338E (pt) 2015-03-05
JP5619810B2 (ja) 2014-11-05
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
EP2503338A3 (en) 2013-03-13
SI2201376T1 (sl) 2012-09-28
DK2201376T3 (da) 2012-10-15
CA2702635A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
JP5619810B2 (ja) 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー
Haffke et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS)
US8975081B2 (en) Biomarker for monitoring development of diseases and assessing the efficacy of therapies
JP6337020B2 (ja) 急性呼吸促迫症候群（ａｒｄｓ）関連バイオマーカーを測定する方法、患者におけるａｒｄｓの進行および治療をモニターする方法
Gorska et al. Comparative study of IL-33 and IL-6 levels in different respiratory samples in mild-to-moderate asthma and COPD
CN106461677B (zh) 肺高血压病的检查方法
JP2023520168A (ja) 無細胞ヌクレオソームレベルを用いるトリアージ方法
Gamil et al. Increased serum levels of asymmetric dimethylarginine and symmetric dimethylarginine and decreased levels of arginine in Sudanese patients with essential hypertension
Kaur et al. ST2 expression and release by the bronchial epithelium is downregulated in asthma
Fernández Pérez et al. Fibrotic hypersensitivity pneumonitis
Vu et al. Deficiency in ST2 signaling ameliorates RSV-associated pulmonary hypertension
Basile et al. Elevated serum polyclonal immunoglobulin free light chains in patients with severe asthma
CN117529664A (zh) 用于预测脓毒症和脓毒性休克的方法
Kusaka et al. Association of exercise-induced pulmonary hypertension with nailfold capillary density in systemic sclerosis: a single-center retrospective observational study
CN104737020B (zh) 早期肾障碍的评价指标和其测定方法
US9759729B2 (en) Blood biomarkers for necrotizing enterocolitis
Nyshchuk-Oliinyk et al. Prognostic factors of chronic coronary syndrome in patients with concomitant type 2 diabetes mellitus
Kivelä et al. Faecal biomarkers in children with coeliac disease: A way forward?
Sumi et al. Regions of Inflammation in mouse asthma correspond to regions of heme-free soluble guanylyl cyclase and can be tracked by marked expression of heme-oxygenase-1
HK40100515A (en) Triaging method using cell free nucleosome levels
CN113495155A (zh) 分诊方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111114

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20111114

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20111130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111206

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120403

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120423

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150427

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4982610

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150427

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R314531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150427

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees